menu
    • menu
    [{"orgOrder":0,"company":"Dynacure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Inapplicable"},{"orgOrder":0,"company":"Dynacure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Inapplicable"},{"orgOrder":0,"company":"Dynacure","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Inapplicable"},{"orgOrder":0,"company":"Dynacure","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2021","type":"Agreement","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Nippon Shinyaku","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Nippon Shinyaku"},{"orgOrder":0,"company":"Dynacure","sponsor":"Perceptive Advisors","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"FRANCE","productType":"Oligonucleotide","year":"2020","type":"Series C Financing","leadProduct":"DYN101","moa":"DNM2","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"Dynacure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Dynacure \/ Perceptive Advisors","highestDevelopmentStatusID":"7","companyTruncated":"Dynacure \/ Perceptive Advisors"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dynacure Receives Fast Track Designation for DYN101, an Investigational Antisense Oligonucleotide for the Trea...

                            Details : Fast Track Designation recieved for DYN101,an investigational antisense product candidate designed to reduce the expression of dynamin 2 protein for the treatment of Myotubular and Centronuclear Myopathies.

                            Product Name : DYN101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            June 01, 2022

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Nippon Shinyaku

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Dynacure Announces Strategic Collaboration and Option Agreement with Nippon Shinyaku

                            Details : Under the terms of the agreement, Nippon Shinyaku has secured opt-in rights to exclusively pursue the development and commercialization of DYN101 in Japan depending on analysis of interim data from the Phase 1/2 study, UNITE-CNM.

                            Product Name : DYN101

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            October 11, 2021

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Nippon Shinyaku

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dynacure Gets Rare Pediatric Disease Designation from U.S. FDA for DYN101 for Myotubular and Centronuclear Myo...

                            Details : U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2), for the treatment of Myotubular and Centronuclear Myopathies...

                            Product Name : DYN101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            July 30, 2020

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dynacure Announces First Patient Dosed in Phase 1 / 2 'UNITE-CNM' Study of DYN101

                            Details : This clinical trial, based on Ionis' technology platform, is the first investigational study testing an antisense medicine to treat Centronuclear Myopathies.

                            Product Name : DYN101

                            Product Type : Oligonucleotide

                            Upfront Cash : Inapplicable

                            May 03, 2020

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed

                            Dynacure

                            France arrow
                            IFT FIRST
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I/ Phase II

                            Sponsor : Perceptive Advisors

                            Deal Size : $54.6 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Dynacure Announces €50M ($55M) Series C Financing

                            Details : Funding supports ongoing Phase 1 / 2 'Unite-CNM' study of DYN101 in Patients with Myotubular and Centronuclear Myopathies.

                            Product Name : DYN101

                            Product Type : Oligonucleotide

                            Upfront Cash : Undisclosed

                            February 04, 2020

                            Lead Product(s) : DYN101

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Perceptive Advisors

                            Deal Size : $54.6 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth